[EN] PYRAZOLOPYRIMIDINE MACROCYCLES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION<br/>[FR] MACROCYCLES DE PYRAZOLOPYRIMIDINE UTILES EN TANT QU'INHIBITEURS DE LA RÉPLICATION DU VIRUS DE L'IMMUNODÉFICIENCE HUMAINE
申请人:BRISTOL MYERS SQUIBB CO
公开号:WO2015126376A1
公开(公告)日:2015-08-27
The disclosure generally relates to compounds of formula I, including compositions and methods for treating human immunodeficiency virus (HIV) infection. The disclosure provides novel inhibitors of HIV, pharmaceutical compositions containing such compounds, and methods for using these compounds in the treatment of HIV infection.
[EN] PYRAZOLOPYRIMIDINE MACROCYCLES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION<br/>[FR] MACROCYCLES DE PYRAZOLOPYRIMIDINE UTILISÉS EN TANT QU'INHIBITEURS DE LA RÉPLICATION DU VIRUS DE L'IMMUNODÉFICIENCE HUMAINE
申请人:BRISTOL MYERS SQUIBB CO
公开号:WO2015126743A1
公开(公告)日:2015-08-27
The disclosure generally relates to compounds of formula I, including compositions and methods for treating human immunodeficiency virus (HIV) infection. The disclosure provides novel inhibitors of HIV integrase, pharmaceutical compositions containing such compounds, and methods for using these compounds in the treatment of HIV infection.
CRYSTALLINE ANTI-TRICHOPHYTON AGENTS AND PREPARATION PROCESS THEREOF
申请人:MEIJI SEIKA PHARMA CO., LTD.
公开号:US20170233346A1
公开(公告)日:2017-08-17
A crystal form of 2-(3,5-dimethyl-1H-pyrazol-1-yl)-5-methylphenol which is stable and has high purity for preservation, industrial manufacturing, and circulation, and process for providing the same by using a boron compound.
[EN] NLRP3 INFLAMMASOME INHIBITORS<br/>[FR] INHIBITEURS DE L'INFLAMMASOME NLRP3
申请人:HANGZHOU HIGHLIGHTLL PHARMACEUTICAL CO LTD
公开号:WO2023186020A1
公开(公告)日:2023-10-05
Provided are compounds of Formula (I): wherein all of the variables are as defined herein, which inhibit NOD-like receptor protein 3 (NLRP3) inflammasome activity. Disclosed are the processes for their preparation, pharmaceutical compositions and medicaments containing them, and their use in the treatment of disease and disorders mediated by NLRP3.